Anti-inflammatory Activity of Magnesium Isoglycyrrhizinate Through Inhibition of Phospholipase A2/Arachidonic Acid Pathway

Inflammation

Volumn 38, Issue 4, 2015, Pages 1639-1648

  Xie, Chunfeng ^a   Li, Xiaoting ^a   Wu, Jieshu ^a   Liang, Zhaofeng ^a   Deng, Feifei ^a   Xie, Wei ^a   Zhu, Mingming ^a   Zhu, Jianyun ^a   Zhu, Weiwei ^a   Geng, Shanshan ^a   Zhong, Caiyun ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

arachidonic acid; inflammatory lipid mediators; inhibition; magnesium isoglycyrrhizinate; phospholipase A2

Indexed keywords

ANTIINFLAMMATORY AGENT; ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; GLYCYRRHIZIC ACID DERIVATIVE; LEUKOTRIENE B4; LIPOPOLYSACCHARIDE; MAGNESIUM ISOGLYCYRRHIZINATE; PHOSPHOLIPASE A2; PROSTACYCLIN; PROSTACYCLIN SYNTHASE; PROSTAGLANDIN E2; THROMBOXANE B2; THROMBOXANE SYNTHASE; UNCLASSIFIED DRUG; 18ALPHA,20BETA-HYDROXY-11-OXO-NOROLEAN-12-EN-3BETA-YL-2-O-BETA-D-GLUCOPYRANUROSYL-ALPHA-D-GLUCOPYRANOSIDURONATE MAGNESIUM TETRAHYDRATE; HERBACEOUS AGENT; SAPONIN; TRITERPENE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; FATTY ACID METABOLISM; INFLAMMATORY CELL; MACROPHAGE; MTT ASSAY; PROTEIN EXPRESSION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; DRUG EFFECTS; METABOLISM; MOUSE; PHYSIOLOGY; SIGNAL TRANSDUCTION;

GLYCYRRHIZA; GLYCYRRHIZA GLABRA;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARACHIDONIC ACID; CELL LINE; DRUGS, CHINESE HERBAL; MACROPHAGES; MICE; PHOSPHOLIPASES A2; SAPONINS; SIGNAL TRANSDUCTION; TRITERPENES;

EID: 84937251391     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-015-0140-2     Document Type: Article

References (54)

1. Xue, T., and R. Roy. 2003. Studying traditional Chinese medicine. Science 300: 740–741.
2. Asl, M.N., and H. Hosseinzadeh. 2008. Review of pharmacological effects of Glycyrrhiza sp. and its bioactive compounds. Phytotherapy Research 22: 709–724.
3. Wang, C.Y., T.C. Kao, W.H. Lo, and G.C. Yen. 2011. Glycyrrhizic acid and 18beta-glycyrrhetinic acid modulate lipopolysaccharide-induced inflammatory response by suppression of NF-kappaB through PI3K p110delta and p110gamma inhibitions. Journal of Agricultural and Food Chemistry 59: 7726–7733.
4. Fuhrman, B., S. Buch, J. Vaya, P.A. Belinky, R. Coleman, T. Hayek, and M. Aviram. 1997. Licorice extract and its major polyphenol glabridin protect low-density lipoprotein against lipid peroxidation: in vitro and ex vivo studies in humans and in atherosclerotic apolipoprotein E-deficient mice. American Journal of Clinical Nutrition 66: 267–275.
5. Vaya, J., P.A. Belinky, and M. Aviram. 1997. Antioxidant constituents from licorice roots: isolation, structure elucidation and antioxidative capacity toward LDL oxidation. Free Radical Biology and Medicine 23: 302–313.
6. Cohen, J.I. 2005. Licking latency with licorice. Journal of Clinical Investigation 115: 591–593.
7. Curreli, F., A.E. Friedman-Kien, and O. Flore. 2005. Glycyrrhizic acid alters Kaposi sarcoma-associated herpes virus latency, triggering p53-mediated apoptosis in transformed B lymphocytes. Journal of Clinical Investigation 115: 642–652.
8. van Rossum, T.G., A.G. Vulto, R.A. de Man, J.T. Brouwer, and S.W. Schalm. 1998. Review article: glycyrrhizin as a potential treatment for chronic hepatitis C. Alimentary Pharmacology and Therapeutics 12: 199–205.
9. Fiore, C., M. Salvi, M. Palermo, G. Sinigaglia, D. Armanini, and A. Toninello. 2004. On the mechanism of mitochondrial permeability transition induction by glycyrrhetinic acid. Biochimica et Biophysica Acta 1658: 195–201.
10. Salvi, M., C. Fiore, D. Armanini, and A. Toninello. 2003. Glycyrrhetinic acid-induced permeability transition in rat liver mitochondria. Biochemical Pharmacology 66: 2375–2379.
11. Gumpricht, E., R. Dahl, M.W. Devereaux, and R.J. Sokol. 2005. Licorice compounds glycyrrhizin and 18beta-glycyrrhetinic acid are potent modulators of bile acid-induced cytotoxicity in rat hepatocytes. Journal of Biological Chemistry 280: 10556–10563.
12. Lin, G., I.P. Nnane, and T.Y. Cheng. 1999. The effects of pretreatment with glycyrrhizin and glycyrrhetinic acid on the retrorsine-induced hepatotoxicity in rats. Toxicon 37: 1259–1270.
13. Kobayashi, M., D.A. Schmitt, T. Utsunomiya, R.B. Pollard, and F. Suzuki. 1993. Inhibition of burn-associated suppressor cell generation by glycyrrhizin through the induction of contrasuppressor T cells. Immunology and Cell Biology 71(Pt 3): 181–189.
14. Raphael, T.J., and G. Kuttan. 2003. Effect of naturally occurring triterpenoids glycyrrhizic acid, ursolic acid, oleanolic acid and nomilin on the immune system. Phytomedicine 10: 483–489.
15. Zhang, Y.H., K. Isobe, F. Nagase, T. Lwin, M. Kato, M. Hamaguchi, T. Yokochi, and I. Nakashima. 1993. Glycyrrhizin as a promoter of the late signal transduction for interleukin-2 production by splenic lymphocytes. Immunology 79: 528–534.
16. Chen, K.J., W.Y. Chen, X. Chen, Y.M. Jia, G.Q. Peng, and L. Chen. 2014. Increased elimination of paclitaxel by magnesium isoglycyrrhizinate in epithelial ovarian cancer patients treated with paclitaxel plus cisplatin: a pilot clinical study. European Journal of Drug Metabolism and Pharmacokinetics 39: 25–31.
17. Cheng, Y., J. Zhang, J. Shang, and L. Zhang. 2009. Prevention of free fatty acid-induced hepatic lipotoxicity in HepG2 cells by magnesium isoglycyrrhizinate in vitro. Pharmacology 84: 183–190.
18. He, Y., F. Zeng, Q. Liu, W. Ju, H. Fu, H. Hao, L. Li, and Y. Xie. 2010. Protective effect of magnesium isoglycyrrhizinate on ethanol-induced testicular injuries in mice. Journal of Biomedical Research 24: 153–160.
19. Mao, Y.M., M.D. Zeng, Y. Chen, C.W. Chen, Q.C. Fu, X. Cai, S.M. Wu, Y.G. Chen, Y. Sun, J. Li, Y.H. Sui, W. Zhao, L.G. Lu, A.P. Cao, and H.Z. Chen. 2009. Magnesium isoglycyrrhizinate in the treatment of chronic liver diseases: a randomized, double-blind, multi-doses, active drug controlled, multi-center study. Zhonghua Gan Zang Bing Za Zhi 17: 847–851.
20. Shoeb, M., U.C. Yadav, S.K. Srivastava, and K.V. Ramana. 2011. Inhibition of aldose reductase prevents endotoxin-induced inflammation by regulating the arachidonic acid pathway in murine macrophages. Free Radical Biology and Medicine 51: 1686–1696.
21. Xu, J., J. Liu, C. Peng, Y. Liu, and J. Hu. 2010. Effect of magnesium isoglycyrrhizinate on allergy contact dermatitis (ACD) in mice. Zhongguo Zhong Yao Za Zhi 35: 1311–1314.
22. Zhang, J.C., G.F. Zheng, M.X. Wu, J.W. Wu, L.Y. Ouyang, and X.Q. Liu. 2012. Effect of magnesium isoglycyrrhizinate on PLA2 during liver tissue injury following limb ischemia/reperfusion in rats. Zhonghua Gan Zang Bing Za Zhi 20: 537–541.
23. Murakami, M., Y. Taketomi, Y. Miki, H. Sato, T. Hirabayashi, and K. Yamamoto. 2011. Recent progress in phospholipase A2 research: from cells to animals to humans. Progress in Lipid Research 50: 152–192.
24. Ueno, N., Y. Taketomi, K. Yamamoto, T. Hirabayashi, D. Kamei, Y. Kita, T. Shimizu, K. Shinzawa, Y. Tsujimoto, K. Ikeda, R. Taguchi, and M. Murakami. 2011. Analysis of two major intracellular phospholipases A(2) (PLA(2)) in mast cells reveals crucial contribution of cytosolic PLA(2)α, not Ca(2+)-independent PLA(2)β, to lipid mobilization in proximal mast cells and distal fibroblasts. Journal of Biological Chemistry 286: 37249–37263.
25. Cao, J., J.E. Burke, and E.A. Dennis. 2013. Using hydrogen/deuterium exchange mass spectrometry to define the specific interactions of the phospholipase A2 superfamily with lipid substrates, inhibitors, and membranes. Journal of Biological Chemistry 288: 1806–1813.
26. Burke, J.E., and E.A. Dennis. 2009. Phospholipase A2 biochemistry. Cardiovascular Drugs and Therapy 23: 49–59.
27. Park, J.Y., M.H. Pillinger, and S.B. Abramson. 2006. Prostaglandin E2 synthesis and secretion: the role of PGE2 synthases. Clinical Immunology 119: 229–240.
28. Jenkins, C.M., A. Cedars, and R.W. Gross. 2009. Eicosanoid signalling pathways in the heart. Cardiovascular Research 82: 240–249.
29. Magrioti, V., and G. Kokotos. 2013. Phospholipase A2 inhibitors for the treatment of inflammatory diseases: a patent review (2010–present). Expert Opinion on Therapeutic Patents 23: 333–344.
30. Chandrasekharan, N.V., and D.L. Simmons. 2004. The cyclooxygenases. Genome Biology 5: 241.
31. Konkle, B.A. 2011. Acquired disorders of platelet function. Hematology American Society Hematology Educational Program 2011: 391–396.
32. Mendes, R.T., C.P. Stanczyk, R. Sordi, M.F. Otuki, F.A. dos Santos, and D. Fernandes. 2012. Selective inhibition of cyclooxygenase-2: risks and benefits. Revista Brasileira de Reumatologia 52: 767–782.
33. Bishayee, K., and A.R. Khuda-Bukhsh. 2013. 5-lipoxygenase antagonist therapy: a new approach towards targeted cancer chemotherapy. Acta Biochimica Biophysica Sinica (Shanghai) 45: 709–719.
34. Chandrasekaran, C.V., H.B. Deepak, P. Thiyagarajan, S. Kathiresan, G.K. Sangli, M. Deepak, and A. Agarwal. 2010. Dual inhibitory effect of Glycyrrhiza glabra (GutGard) on COX and LOX products. Phytomedicine 18: 278–284.
35. Shoeb, M., and K.V. Ramana. 2011. Anti-inflammatory effects of benfotiamine are mediated through the regulation of the arachidonic acid pathway in macrophages. Free Radical Biology and Medicine 52: 182–190.
36. Won, J.S., Y.B. Im, M. Khan, A.K. Singh, and I. Singh. 2005. Involvement of phospholipase A2 and lipoxygenase in lipopolysaccharide-induced inducible nitric oxide synthase expression in glial cells. Glia 51: 13–21.
37. Barnes, P.J. 2006. Corticosteroids: the drugs to beat. European Journal of Pharmacology 533: 2–14.
38. Barnes, P.J. 2010. Mechanisms and resistance in glucocorticoid control of inflammation. Journal of Steroid Biochemistry and Molecular Biology 120: 76–85.
39. Zhang, Q., and M. Ye. 2009. Chemical analysis of the Chinese herbal medicine Gan-Cao (licorice). Journal of Chromatography A 1216: 1954–1969.
40. Sun, L., J. Shen, X. Pang, L. Lu, Y. Mao, and M. Zeng. 2007. Phase I safety and pharmacokinetic study of magnesium isoglycyrrhizinate after single and multiple intravenous doses in Chinese healthy volunteers. The Journal of Clinical Pharmacology 47: 767–773.
41. Clark, J.D., L.L. Lin, R.W. Kriz, C.S. Ramesha, L.A. Sultzman, A.Y. Lin, N. Milona, and J.L. Knopf. 1991. A novel arachidonic acid-selective cytosolic PLA2 contains a Ca(2+)-dependent translocation domain with homology to PKC and GAP. Cell 65: 1043–1051.
42. Su, A.I., M.P. Cooke, K.A. Ching, Y. Hakak, J.R. Walker, T. Wiltshire, A.P. Orth, R.G. Vega, L.M. Sapinoso, A. Moqrich, A. Patapoutian, G.M. Hampton, P.G. Schultz, and J.B. Hogenesch. 2002. Large-scale analysis of the human and mouse transcriptomes. Proceedings of the National Academy of Sciences of the United States of America 99: 4465–4470.
43. Sanchez, T., and J.J. Moreno. 2002. Calcium-independent phospholipase A2 through arachidonic acid mobilization is involved in Caco-2 cell growth. Journal of Cellular Physiology 193: 293–298.
44. Martínez, J., and J.J. Moreno. 2001. Role of Ca2+−independent phospholipase A2 on arachidonic acid release induced by reactive oxygen species. Archives of Biochemistry and Biophysics 392: 257–262.
45. Murakami, M., and G. Lambeau. 2013. Emerging roles of secreted phospholipase A(2) enzymes: an update. Biochimie 95: 43–50.
46. Vane, J.R., Y.S. Bakhle, and R.M. Botting. 1998. Cyclooxygenases 1 and 2. Annual Review of Pharmacology and Toxicology 38: 97–120.
47. Lee, C.H., H.K. Kim, J.M. Kim, O. Ayush, S.Y. Im, D.K. Oh, and H.K. Lee. 2012. Glutamine suppresses airway neutrophilia by blocking cytosolic phospholipase A(2) via an induction of MAPK phosphatase-1. Journal of Immunology 189: 5139–5146.
48. Vincentini, O., M.G. Quaranta, M. Viora, C. Agostoni, and M. Silano. 2011. Docosahexaenoic acid modulates in vitro the inflammation of celiac disease in intestinal epithelial cells via the inhibition of cPLA2. Clinical Nutrition 30: 541–546.
49. Kirincich, S.J., J. Xiang, N. Green, S. Tam, H.Y. Yang, J. Shim, M.W. Shen, J.D. Clark, and J.C. McKew. 2009. Benzhydrylquinazolinediones: novel cytosolic phospholipase A2alpha inhibitors with improved physicochemical properties. Bioorganic and Medicinal Chemistry 17: 4383–4405.
50. Lee, K.L., M.L. Behnke, M.A. Foley, L. Chen, W. Wang, R. Vargas, J. Nunez, S. Tam, N. Mollova, X. Xu, M.W. Shen, M.K. Ramarao, D.G. Goodwin, C.L. Nickerson-Nutter, W.M. Abraham, C. Williams, J.D. Clark, and J.C. McKew. 2008. Benzenesulfonamide indole inhibitors of cytosolic phospholipase A2alpha: optimization of in vitro potency and rat pharmacokinetics for oral efficacy. Bioorganic and Medicinal Chemistry 16: 1345–1358.
51. Lee, K.L., M.A. Foley, L. Chen, M.L. Behnke, F.E. Lovering, S.J. Kirincich, W. Wang, J. Shim, S. Tam, M.W. Shen, S. Khor, X. Xu, D.G. Goodwin, M.K. Ramarao, C. Nickerson-Nutter, F. Donahue, M.S. Ku, J.D. Clark, and J.C. McKew. 2007. Discovery of Ecopladib, an indole inhibitor of cytosolic phospholipase A2alpha. Journal of Medicinal Chemistry 50: 1380–1400.
52. McKew, J.C., M.A. Foley, P. Thakker, M.L. Behnke, F.E. Lovering, F.W. Sum, S. Tam, K. Wu, M.W. Shen, W. Zhang, M. Gonzalez, S. Liu, A. Mahadevan, H. Sard, S.P. Khor, and J.D. Clark. 2006. Inhibition of cytosolic phospholipase A2alpha: hit to lead optimization. Journal of Medicinal Chemistry 49: 135–158.
53. McKew, J.C., K.L. Lee, M.W. Shen, P. Thakker, M.A. Foley, M.L. Behnke, B. Hu, F.W. Sum, S. Tam, Y. Hu, L. Chen, S.J. Kirincich, R. Michalak, J. Thomason, M. Ipek, K. Wu, L. Wooder, M.K. Ramarao, E.A. Murphy, D.G. Goodwin, L. Albert, X. Xu, F. Donahue, M.S. Ku, J. Keith, C.L. Nickerson-Nutter, W.M. Abraham, C. Williams, M. Hegen, and J.D. Clark. 2008. Indole cytosolic phospholipase A2 alpha inhibitors: discovery and in vitro and in vivo characterization of 4-{3-[5-chloro-2-(2-{[(3,4-dichlorobenzyl)sulfonyl]amino}ethyl)-1-(diphenylmethyl)-1H-indol-3-yl]propyl}benzoic acid, efipladib. Journal of Medicinal Chemistry 51: 3388–3413.
54. Charlier, C., and Michaux, C. 2003. Dual inhibition of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) as a new strategy to provide safer non-steroidal anti-inflammatory drugs. European Journal of Medicinal Chemistry 38: 645–659.